IN VITRO, IN VIVO, ACOUSTIC CHARACTERIZATION--AEROSOMES

描述(摘自申请者摘要)：诊断超声 这可能代表着全球每年10亿美元的市场。这个 申请者的具体目标和长期目标涉及发展 一种高效低成本的超声造影剂的研究 图像敏感度，申请者认为可以成为 各种诊断程序的行业标准(即 肝脾成像，心脏成像和室壁运动研究，血液- 池成像[血管瘤]和血管血流研究)。这项研究 方法学将包括关键的体外、体内和声学 帮助申请组织ImaRx的特性研究 在确定它的应用潜力方面，制药。这个 这项研究的意义可以提供一种手段， 由于使用诊断成像，降低了医疗保健成本 使用超声波的气雾体可能成为高质量的 现有成本更高的诊断程序的可靠替代方案 (核磁共振、CT等)。这可能会对小型企业特别有利 社区医院以及第三方工作的医疗保健问题 使用超声波的气雾体可以提供高质量、低成本 诊断性医疗保健。第二阶段的目标包括：声学 表征.货架寿命稳定性的测定.进行 详细的药理学和毒理学；进行详细的 生物分布研究，进行进一步的成像研究，以及 启动I期临床试验计划。

DESCRIPTION (Adapted from Applicant's Abstract): Diagnostic ultrasound potentially represents a billion dollar a year market worldwide. The applicants' specific aims and longterm objective involve the development of an efficient and low-cost ultrasound contrast agent with improved image sensitivity such that the applicants believe could become the industry standard for a variety of diagnostic procedures (i.e. hepatosplenic imaging, cardiac imaging and wall-motion studies, blood- pool imaging [hemangiomas], and vascular flow studies). The research methodology would involve critical in vitro, in vivo, and acoustic characterization studies to aid the applicant organization, ImaRx Pharmaceutical, in determining the potential for it's application. The implications of the research could provide a means for substantially reduced health-care costs with regard to diagnostic imaging as the use of Aerosomes with ultrasound potentially could become a high quality and reliable alternative to existing, more costly, diagnostic procedures (MRI, CT, etc.). This could become particularly beneficial for small community hospitals as well as third work health care concerns as Aerosomes with ultrasound could provide high quality, low cost diagnostic healthcare. Goals of Phase II would include: acoustic characterization; shelf life stability determination; conduct of detailed pharmacology and toxicology; conduct of detailed biodistribution studies, conduct of further imaging studies, and initiate planning of Phase I clinical trials.